FDA halts clinical trial of Regado Biosciences clotting drug
Related Blog Posts
- Regado Biosciences completes IPO, raises $43M
- Regado Biosciences cutting jobs at Durham operation
- Duke spinout Regado Biosciences goes public - but for less cash that hoped
- Another RTP biotech company files to go public
On The Web
The clinical hold follows Regado’s July 2 announcement that it would voluntarily stop its trial of Revolixys Kit after the Data Safety Monitoring Board started an unplanned review of the data from the study. New Jersey-based Regado, which maintains R&D labs in Durham, said at the time the review of data for all 3,234 patients enrolled to date would take eight weeks. The review is focusing on serious adverse events and allergic reactions. Regado and the clinical sites conducting the trials will remain blinded to the study findings during the review.
Regado went public last August at $4 per share, raising $43 million. The company’s stock has traded as high as $14.10 per share. But Regado stock took a hit with the latest news and its shares fell by as much as 6 percent Thursday, trading at $2.53 per share in mid-afternoon Trading.
Revolixys, formerly known as REG-1, is based on technology originally developed at Duke University. The drug is being studied in a worldwide phase 3 trial comparing it to another drug, bivalirudin, in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
"As announced earlier, we remain blinded to REGULATE-PCI study data and are awaiting the outcome of the full safety and efficacy analysis, including an analysis of benefit/risk ratio, being performed by our Data and Safety Monitoring Board (DSMB). Any recommendation to re-initiate patient enrollment in REGULATE-PCI will be based on the DSMB's conclusions and would always be implemented in agreement with FDA," Regado CEO David Mazzo said in a statement.
Please Log In to add a comment.
Best of TechWire Insider
- Meet the 'born multi-tasker' bringing Startup Grind to Raleigh
- House won't 'concur' on bill with crowdfunding, but ...
- Lenovo dials up global smartphone share in record quarter
- Offering a stipend to startups, Groundwork Labs demonstrates its own growth
- Report: Motorola Mobility sales surging ahead of Lenovo deal close
- Wedding bell blues? Not at Raleigh startup WedPics
- Lenovo catches Internet of Things fever - is it good idea?
- N.C. Senate OKs bill with crowdfunding but future is 'uncertain'
- National tech news site Xconomy launches in RTP
- Vivek Wadhwa blasts Twitter's 'proud' response to diversity report